NEW YORK, Nov. 8, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of William Lyon Homes ("WLH" or the "Company") (NYSE: WLH) in connection with the proposed acquisition of the Company by Taylor Morrison Home Corp. (NYSE: TMHC) ("TMHC"). Under the terms of the acquisition agreement, WLH shareholders will receive 0.80 shares of TMHC and $2.50 in cash for each WLH share they own, representing consideration of $19.86 based on TMHC's November 6 trading price of $21.70.
If you own WLH shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th Floor New York, NY 10036 (212) 682-3025 (888) 593-4771 [email protected]
WeissLaw is investigating whether WLH's Board acted to maximize shareholder value prior to entering into the acquisition agreement. Notably, at least one analyst set a target price of $22.00 per WLH share, or $2.14 above the per-share consideration.
Finally, the acquisition of WLH is a strategic transaction which will position TMHC as the fifth largest builder in the United States.
Given these facts, WeissLaw is concentrating its investigation on whether the acquisition enhances shareholder value. WeissLaw is concerned whether the proposed acquisition undervalues the Company, and whether all material information related to the proposed acquisition is fully and fairly disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]